TRIM37 Promotes Pancreatic Cancer Progression through Modulation of Cell Growth, Migration, Invasion, and Tumor Immune Microenvironment.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
21 Jan 2022
Historique:
received: 31 10 2021
revised: 19 01 2022
accepted: 19 01 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 5 3 2022
Statut: epublish

Résumé

TRIM37 dysregulation has been observed in several cancer types, implicating its possible role in tumorigenesis. However, the role of TRIM37 in pancreatic cancer progression remains unclear. In the present study, we observed that TRIM37 knockdown resulted in reduced proliferation, clonogenicity, migration, and invasion ability of pancreatic cancer cells. Furthermore, an in vivo study using an orthotopic syngeneic animal model further confirmed that reduced expression of TRIM37 in cancer cells suppressed tumor growth in vivo. Moreover, in mice bearing TRIM37 knockdown pancreatic cancer cells, the proportion of CD11b

Identifiants

pubmed: 35163097
pii: ijms23031176
doi: 10.3390/ijms23031176
pmc: PMC8835669
pii:
doi:

Substances chimiques

Tripartite Motif Proteins 0
TRIM37 protein, human EC 2.3.2.27
Ubiquitin-Protein Ligases EC 2.3.2.27

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : China Medical University Hospital Taiwan
ID : DMR-107-033
Organisme : China Medical University Taiwan
ID : CMU103-S-27

Références

Nature. 2007 Oct 25;449(7165):1073-7
pubmed: 17960246
Dev Cell. 2013 Jun 24;25(6):555-71
pubmed: 23769972
Gut. 2018 Jun;67(6):1112-1123
pubmed: 29196437
Trends Biochem Sci. 2017 Apr;42(4):297-311
pubmed: 28118948
Int J Mol Sci. 2018 Dec 24;20(1):
pubmed: 30586926
PLoS One. 2011 Feb 02;6(2):e16786
pubmed: 21311774
BMC Immunol. 2011 Aug 04;12:43
pubmed: 21813021
Oncol Lett. 2017 Dec;14(6):6365-6372
pubmed: 29163677
J Cell Biol. 2017 Sep 4;216(9):2843-2858
pubmed: 28724525
J Clin Invest. 2011 Dec;121(12):4746-57
pubmed: 22056381
Autophagy. 2018;14(9):1574-1585
pubmed: 29940807
Cancer Res. 2003 May 1;63(9):2005-9
pubmed: 12727809
Biochem Biophys Res Commun. 2021 Jun 4;556:87-92
pubmed: 33839419
J Mol Signal. 2013 Jun 13;8(1):7
pubmed: 23758787
Cancer Cell. 2016 Jun 13;29(6):832-845
pubmed: 27265504
Oncoimmunology. 2015 Nov 24;5(3):e1115177
pubmed: 27141367
J Exp Med. 2012 Aug 27;209(9):1671-87
pubmed: 22908323
J Biol Chem. 2001 Jun 29;276(26):24242-52
pubmed: 11279055
Onco Targets Ther. 2018 Dec 10;11:8803-8813
pubmed: 30573971
World J Gastroenterol. 2014 Aug 28;20(32):11182-98
pubmed: 25170203
Cancer Discov. 2016 Apr;6(4):400-413
pubmed: 26896096
Oncoimmunology. 2017 Nov 20;7(3):e1393598
pubmed: 29399390
Cancer Res. 2018 Nov 15;78(22):6399-6412
pubmed: 30254148
World J Gastroenterol. 2018 May 21;24(19):2047-2060
pubmed: 29785074
J Exp Clin Cancer Res. 2021 Jun 15;40(1):195
pubmed: 34130705
Adv Exp Med Biol. 2007;597:1-24
pubmed: 17633013
Gut. 2012 Oct;61(10):1488-500
pubmed: 21873467
Cancer Res. 1998 Aug 1;58(15):3391-400
pubmed: 9699671
Trends Cancer. 2017 Oct;3(10):686-697
pubmed: 28958387
Onco Targets Ther. 2018 Nov 08;11:7935-7945
pubmed: 30510432
J Pathol. 2018 Nov;246(3):366-378
pubmed: 30043491
Cancer Sci. 2018 Dec;109(12):3826-3839
pubmed: 30259595
Br J Cancer. 2014 Aug 26;111(5):817-22
pubmed: 24755884
Exp Cell Res. 2005 Aug 1;308(1):146-55
pubmed: 15885686
Nat Commun. 2018 Feb 8;9(1):582
pubmed: 29422500
World J Gastroenterol. 2014 Aug 28;20(32):11160-81
pubmed: 25170202
Biochem Biophys Res Commun. 2015 Sep 4;464(4):1120-1127
pubmed: 26208456
Cancers (Basel). 2020 Oct 06;12(10):
pubmed: 33036138
Biomed Pharmacother. 2018 Mar;99:59-64
pubmed: 29324313
Nature. 2014 Dec 4;516(7529):116-20
pubmed: 25470042
EBioMedicine. 2019 Sep;47:98-113
pubmed: 31495721
J Pathol. 2009 Jun;218(2):163-71
pubmed: 19334051
Curr Opin Immunol. 2013 Apr;25(2):200-5
pubmed: 23422836
Nature. 2016 Oct 20;538(7625):378-382
pubmed: 27732578
Oncol Res. 2017 Jan 2;25(1):115-122
pubmed: 28081740
Tumour Biol. 2016 Feb;37(2):2629-34
pubmed: 26395261

Auteurs

Tuyen Thi Do (TT)

International Master's Program of Biomedical Sciences, College of Medicine, China Medical University, Taichung 404328, Taiwan.
Department of Laboratory Hematology, Hanoi Medical University, Hanoi 11520, Vietnam.

Chun-Chieh Yeh (CC)

Department of Surgery, School of Medicine, China Medical University, Taichung 404328, Taiwan.
Organ Transplantation Center, Department of Surgery, China Medical University Hospital, Taichung 404327, Taiwan.
Department of Surgery, Asia University Hospital, Taichung 413505, Taiwan.

Guo-Wei Wu (GW)

Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404328, Taiwan.

Chia-Chen Hsu (CC)

Department of Biological Science and Technology, China Medical University, Taichung 404328, Taiwan.

Hung-Chih Chang (HC)

Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404328, Taiwan.
Department of Microbiology and Immunology, School of Medicine, China Medical University, Taichung 404328, Taiwan.

Hui-Chen Chen (HC)

Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404328, Taiwan.
Department of Microbiology and Immunology, School of Medicine, China Medical University, Taichung 404328, Taiwan.
Research and Development Center for Immunology, China Medical University, Taichung 404328, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH